UCB SA (UNC.F)
| Previous close | 137.45 |
| Open | 136.65 |
| Bid | 0.00 x 30700 |
| Ask | 0.00 x 30700 |
| Day's range | 136.65 - 136.65 |
| 52-week range | 65.68 - 138.50 |
| Volume | |
| Avg. volume | 81 |
| Market cap | 26.398B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 77.64 |
| EPS (TTM) | 1.76 |
| Earnings date | 24 July 2024 - 03 Aug 2024 |
| Forward dividend & yield | 1.36 (1.00%) |
| Ex-dividend date | 26 Apr 2024 |
| 1y target est | N/A |
Simply Wall St.Top Value Stocks That Could Be Bargains In June 2024
As global markets continue to navigate through political uncertainties and mixed economic signals, investors are keenly observing shifting trends across various indices. With the S&P 500 and Nasdaq reaching new highs amid a narrow market advance, discerning investors might find potential opportunities in undervalued stocks that could emerge as bargains.
PR NewswireNew CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels
UCB, a global biopharmaceutical company, will present results from three studies for CIMZIA® (certolizumab pegol), a PEGylated fragment crystalized (Fc)-free tumor necrosis factor inhibitor (TNFi), for women of childbearing age living with chronic immune-mediated diseases and people with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels.1,2,3 These data will be presented at the European Congress of Rheumatology, EULAR 2024, and provide evidence to inform personalized treatment dec
PR NewswireUCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
UCB, a global biopharmaceutical company, today announced the first presentation of two-year data from the Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension (OLE), BE MOVING, evaluating BIMZELX, an interleukin (IL)-17A and IL-17F inhibitor, in the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis. The impact of BIMZELX treatment on two-year radiographic progression in
